Predisposition to develop melanoma results from a complex, multifactorial etiology that involves genetic factors, endogenous physiology, and exogenous exposures. The interaction of these factors to cause melanoma may differ by age, race, or family history. Knowledge about multiple risk factors in melanoma etiology will aid in the identification of individuals at increased risk for developing melanoma. Ultimately, this knowledge may facilitate melanoma prevention strategies. We propose to study candidate genetic biomarkers of melanoma risk, and determine their association with melanoma phenotypes. The underlying biological hypothesis of the proposed research is that susceptibility to develop melanoma stems from the complex interactions of multiple factors, including inherited genotypes associated with immune surveillance. To address this hypothesis, we will use a multidisciplinary approach that involves methods drawn from molecular biology and epidemiology to evaluate the role of genes involved in melanogenesis and development of a melanoma. We propose to consider the role candidate melanogenesis genes (i.e., cytokines and other immune surveillance genes (ISG)), the interaction of these genes and other melanoma risk factors (e.g., skin/hair/eye pigmentation, previous UV exposure, history of dysplastic nevi, and family history of melanoma) in the etiology of melanoma. Using the existing infrastructure of the Pigmented Lesion Group at the University of Pennsylvania, we propose a case-control study that will directly address the complex, multifactorial etiology of melanoma that involves the interaction of genotypes involved in immune surveillance. This study will address a number of specific hypotheses. First, we will characterize the frequency distribution of alleles at candidate susceptibility genotypes. Second, we will evaluate whether genotypes are associated with tumor characteristics including stage, grade, and age at diagnosis. Finally, we will evaluate whether these genotypes are involved in melanoma etiology, and whether these genotypes interact with one another and other melanoma risk factors. In order to address these hypotheses, we will undertake a study using the extensive resources of the Pigmented Lesion Group at the University of Pennsylvania. The sample will consist of 1000 melanoma cases and 1000 controls. Risk factor information will be obtained by questionnaire, a DNA biosample will be collected using a non-invasive cheek swab method, and diagnostic pathology information will be collected using a systematic approach. Analyses will be undertaken to evaluate the role of candidate genotypes and other risk factors in melanoma etiology, including genotype by environment interactions.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA093372-02
Application #
6660498
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2002-09-28
Project End
2003-09-27
Budget Start
Budget End
Support Year
2
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Wistar Institute
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Ojha, Rani; Leli, Nektaria M; Onorati, Angelique et al. (2018) ER translocation of the MAPK pathway drives therapy resistance in BRAF mutant melanoma. Cancer Discov :
Kugel 3rd, Curtis H; Douglass, Stephen M; Webster, Marie R et al. (2018) Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. Clin Cancer Res 24:5347-5356
Nti, Akosua A; Serrano, Leona W; Sandhu, Harpal S et al. (2018) FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA: Preliminary Results From a Phase I/II Clinical Treatment Trial. Retina :
Onorati, Angelique V; Dyczynski, Matheus; Ojha, Rani et al. (2018) Targeting autophagy in cancer. Cancer 124:3307-3318
Noguera-Ortega, Estela; Amaravadi, Ravi K (2018) Autophagy in the Tumor or in the Host: Which Plays a Greater Supportive Role? Cancer Discov 8:266-268
Rebecca, Vito W; Nicastri, Michael C; Fennelly, Colin et al. (2018) PPT1 promotes tumor growth and is the molecular target of chloroquine derivatives in cancer. Cancer Discov :
Garman, Bradley; Anastopoulos, Ioannis N; Krepler, Clemens et al. (2017) Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines. Cell Rep 21:1936-1952
Rebecca, Vito W; Nicastri, Michael C; McLaughlin, Noel et al. (2017) A Unified Approach to Targeting the Lysosome's Degradative and Growth Signaling Roles. Cancer Discov 7:1266-1283
Ndoye, Abibatou; Budina-Kolomets, Anna; Kugel 3rd, Curtis H et al. (2017) ATG5 Mediates a Positive Feedback Loop between Wnt Signaling and Autophagy in Melanoma. Cancer Res 77:5873-5885
Taylor, Laura A; Abraham, Ronnie M; Tahirovic, Emin et al. (2017) High ALDH1 expression correlates with better prognosis in tumorigenic malignant melanoma. Mod Pathol 30:634-639

Showing the most recent 10 out of 106 publications